Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis: a Prospective Pilot Intervention Study
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease; Psoriasis
- Focus Pharmacokinetics
- Acronyms VIDEO
- 13 Jan 2025 Planned number of patients changed from 50 to 56.
- 13 Jan 2025 Planned End Date changed from 30 Jun 2025 to 6 Jan 2027.
- 13 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jul 2026.